Multidisciplinary Tumor Boards: Integrating Best Patient Care and Education in Precision Medicine
Reinhard Büttner, MD+more
One of the pillars of organ-specific tumor centers certified by the German Cancer Society, such as lung, breast, and prostate cancer centers, is a weekly multidisciplinary tumor board (MTD). In […] Read more
The Rationale for Local Consolidation Therapy in Oncogene-Driven NSCLC
Mehmet Altan+more
The availability of effective TKIs for patients with metastatic NSCLC with targetable oncogenes such as EGFR, ALK, ROS1, and BRAF has transformed the treatment landscape, extending median expected OS from […] Read more
A Decade of Changes in Lung Cancer, with More to Come
Dr. Joan SchillerUsing data from SEER databases, Howlader and colleagues recently reported that incidence-based mortality from NSCLC in men decreased from 6.3% annually (95% CI, 3.4 to 9.0) from 2013 through 2016, in contrast to the period […] Read more
Stage IIIA NSCLC: A Review of Recent and Ongoing Trials
Mariano ProvencioTrial data can help inform change to standard of care, but at what point do we say enough data is enough and move forward with combination therapy as the new standard of care? Read more
Building and Maintaining a Patient–Physician Relationship in the COVID-19 Era
Robert Ramierz, DOAs oncologists, we recognize that the patient–physician relationship is of utmost importance in establishing the patient’s trust in the physician and in the physician’s ability to learn more about the patient’s needs and perform accurate assessments for […] Read more
Multidisciplinary Tumor Board: A Single Institution’s Perspective
Ari Rosenberg, MDAs 7:00 AM approaches, the ninth-floor conference room slowly fills as team members fi le in and find their seats. The senior radiation oncologist identifies his seat in the front row, carefully placing his stack […] Read more
Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic
Harpreet Singh, MDHarpreet Singh, MD, is director of Division of Oncology 2 at the U.S. Food and Drug Administration (FDA). In the following interview, she discusses the FDA’s response to the COVID-19 […] Read more
Coronavirus disease-2019 (COVID-19) is a novel infectious disease, mainly affecting the respiratory tract, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). COVID-19 emerged in Wuhan, China, in December […] Read more
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapies
Sanja Dacic+more
Treatment guidelines recommend neoadjuvant or adjuvant therapies with surgery for patients with large primary tumors or clinical evidence of intrathoracic nodal spread.1,2 A recent joint IASLC–U.S. Food and Drug Administration […] Read more
Small Steps Forward in SCLC: Is a Giant Leap on the Horizon?
Carl M. GayThe absence of an OS benefit in more than 3 decades of clinical trials for extensive-stage SCLC (ES-SCLC) had become an all-too-familiar refrain among the introductions to numerous publications and […] Read more